Coronary Artery Disease, Valvular Heart Disease, Surgical Blood Loss
Conditions
Keywords
CABG, OPCAB, Heart Valve Surgery, Tranexamic Acid, Postoperative Bleeding, Blood Product Transfusion
Brief summary
This is a single-center, double-blind, randomized controlled trial (RCT) comparing two groups of application of topical dose of tranexamic acid (TxA) versus placebo in patients undergoing coronary artery bypass graft (CABG), off pump coronary bypass graft cardiac surgery (OPCAB), and adult heart valve surgery. The primary outcomes of this study comprised of two parameters; post operative bleeding and blood product transfusion. The primary outcomes were assessed during the operation, until 48-hour post operative.
Detailed description
A single center randomized controlled trial (RCT) was conducted at Harapan Kita National Cardiovascular Center, Jakarta, Indonesia as the tertiary cardiovascular referral hospital. The RCT was conducted from October 1 th, 2022 until January 6 th, 2023 (current status: completed). This study aims to determine whether topical tranexamic acid is more effective on the amount of bleeding and the need for postoperative blood product transfusion compared with placebo in patients undergoing cardiac surgery and specifically measure the difference outcome between coronary artery bypass graft (CABG), off pump coronary bypass graft cardiac surgery (OPCAB), and adult heart valve surgery. The control group in this study is given 100 mL of normal saline. The subjects were adults undergoing elective cardiac surgery (CABG, OPCAB, and heart valve surgery). Both the patients and the principal investigators were blinded for the treatment-control allocation. The patients were purposively selected and were randomly assigned to one of the arms with block randomization. The primary outcomes of this study comprised of two parameters; post operative bleeding and blood product transfusion. The primary outcomes were assessed during the operation, until 48-hour post operative.
Interventions
Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
DRUGnormal saline
Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
Sponsors
Indonesia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Subjects were not aware of the arms/treatment given as they were under general anesthesia during the application of interventions being studied. Besides, during the informed consent for the elective cardiac surgery, subjects were extensively given explanation of the purpose, methods, benefits and risks of the procedure including the randomized nature of the allocation to either arms of the study. Principal investigators as well as outcomes assessor were kept unaware of the randomization of interventions as they both were restricted for assessing the patients' medical record and the patient identity were coded in the primary database.
Intervention model description
A double-blind, single center, parallel phase 4 randomized clinical trial was conducted with two intervention arms: an intervention arm with the use of tranexamic acid topical and a control arm with the use of normal saline in which the subjects' recruitment and treatment were conducted simultaneously by means of a block randomization.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients ages \> 18 years old * Patients who are scheduled electively for cardiac surgery in National Heart Center Harapan Kita, Jakarta, Indonesia * Patients with heart valve disease indicated for aortic or mitral repair/replace * Patients with coronary artery disease indicated for CABG or OPCAB surgery * Aortic and/ mitral valve surgery concomitant with tricuspid repair * Patients who are agreed to participate in this study
Exclusion criteria
* Not willing to become research subjects * Allergy to tranexamic acid * Undergoing minimally invasive surgery * Undergoing double valve (aorta & mitral) procedure and double procedure (CABG+valve, valve+maze) * Emergency surgery * History of bleeding disorder or coagulopathy * History of thromboembolic or hemorrhagic disease * Active Infective endocarditis * History of previous cardiac surgery * Estimated glomerular filtration rate \<30 mL/min or on dialysis * Receiving oral therapy with clopidogrel, aspirin, dabigatran, or rivaroxaban in the last five days * Receiving chronic warfarin therapy who have not stopped their medication and have an international normalized ratio (INR) \>1.5 before surgery * Pre-operative thrombocytopenia (\<50,000 platelets per µL) * Pregnancy or breast feeding * Refusal of blood products * Pericarditis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Initial Postoperative bleeding | immediately after the surgery | The study parameter is assessed by postoperative chest tube production immediately after the surgery |
| 6-hour postoperative bleeding | within 6-hour after the surgery | The study parameter is asses the accumulation of drain production within 6 hours postoperatively after surgical procedure |
| 24-hour postoperative bleeding | within 24-hour after the surgery | The study parameter is asses the accumulation of drain production within 24 hours postoperatively after surgical procedure |
| 48-hour postoperative bleeding | within 48-hour after the surgery | The study parameter is asses the accumulation of drain production within 48 hours postoperatively after surgical procedure |
| Postoperative blood product transfusion | participants will be followed for the duration of ICU and intermediate ward stay, an expected average of 5-7 days | The amount of red blood cell, fresh frozen plasma, thrombocyte concentrate, and cryoprecipitate transfusions the patient receive postoperatively during their stay in the hospital. |
Countries
Indonesia
Outcome results
None listed